Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has begun an exploratory feasibility study assessing a selected delivery mechanism for its intranasal therapeutic drug SPC-15 in the treatment of post-traumatic stress syndrome (“PTSD”). The company is partnering with a developer and manufacturer of innovative drug-delivery systems and technology for the study. According to the announcement, Silo Pharma’s Investigational New Drug (“IND”) submission for SPC-15 is on target. A novel serotonin 4 receptor agonist against stress, SPC-15 was developed in conjunction with Columbia University. The therapeutic drug, whose core technology is patent protected, utilizes biomarkers for the treatment of stress-induced affective disorders, anxiety and PTSD. “We believe our research partner’s patented proprietary nasal-to-brain technology could be well suited for the delivery of SPC-15,” said Silo Pharma CEO Eric Weisblum in the press release. “We expect to receive the results of these in vitro lab tests by the end of September. If the results are positive, we will work to prepare an Investigational New Drug application for submission to the FDA in the first quarter of 2024.”
To view the full press release, visit https://ibn.fm/thg9I
About Silo Pharma Inc.
Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research that the company believes will be transformative to the well-being of patients and the healthcare industry. For more information about the company, visit www.SiloPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]
InvestorWire is powered by IBN